Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Latest bid for India's...

    Latest bid for India's Fortis "more risky", says Manipal CEO

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-05-08T11:09:12+05:30  |  Updated On 8 May 2018 11:09 AM IST
    Latest bid for Indias Fortis more risky, says Manipal CEO

    India's privately held Manipal Hospitals had to take a "more risky" approach in its latest bid for domestic rival Fortis Healthcare to see off rival suitors, Manipal's Chief Executive Ranjan Pai told Reuters.


    Manipal on Sunday sweetened its bid for Fortis, offering to inject 21 billion rupees ($312.8 million) to help the ailing hospital operator meet its immediate cash needs, a move that Pai said was risky because Fortis is embroiled in a regulatory investigation that is clouding its prospects.

    In its previous bid Manipal and consortium partner TPG Capital had proposed to take over Fortis at the same valuation of 160 rupees a share, or a total valuation of 83.58 billion rupees ($1.24 billion), without offering any initial cash injection.

    "Yes, this is a more risky structure ... because we don't know what's going to come out of the SFIO," Pai said on Monday, referring to India's Serious Fraud Investigation Office.

    The SFIO is investigating allegations that Fortis founders Malvinder Singh and Shivinder Singh took funds from the company. The duo, who have since left the company, deny wrong doing.

    In March Fortis said it was looking into the allegations and that it expected the SFIO investigation to end in less than a year.

    Fortis has been a target of five firms and investment groups vying for control of its 30-odd hospitals across India. Among them is Malaysia's IHH Healthcare, which wants to invest as much as 40 billion rupees at 175 rupees a share, higher than the share price offered by Manipal.

    TRACK RECORD



    Manipal did not want to be "irrational" in its bid, Pai said, adding that it brought a lot of value to Fortis and its investors with its experience in running hospitals and track record of providing good exit for private equity players.

    "I think, beyond price, people have to look at what is good for the company in the medium to long term," he said, adding that Manipal did not want to enter at a very high price and disappoint investors later if the share price falls.

    Indian businessmen Sunil Munjal and Anand Burman have also offered to buy a stake in Fortis at 167 rupees a share as part of their offer totalling 18 billion rupees.

    Radiant Life Care, backed by private equity firm KKR & Co and China's Fosun International, are the other Fortis suitors.

    Pai said he did not expect the deal to face antitrust hurdles because the combined company's market share will be in "single digits" and a merger should take six to nine months to complete.

    If a deal goes through, TPG will own about 14 percent the new Fortis, while Manipal's founder company and other investors will together own 35.4 percent.

    Pai said that Manipal has held talks with many of the long-term and major investors at Fortis.

    "We want to assure them that if we are given control of the company, corporate governance levels and transparency will be at the highest."
    allegationsAnand BurmanbidChina Fosun InternationalFortisFortis HealthcareIHH HealthcareMalvinder SinghManipal HospitalsRadiant Life CareRanjan PaiSerious Fraud Investigation OfficeSFIOShivinder SinghSunil MunjalTPG
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok